The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients
Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, discusses new quadruplet regimens for newly diagnosed multiple myeloma (MM), specifically daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd). Dr Landgren also covers the bone marrow-based and longitudinal blood-based MRD tracking of this group. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
